Related Experiment Video

Updated: Jul 14, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Blocking anti-apoptosis as a strategy for cancer chemotherapy: NF-kappaB as a target

N R Monks1, D K Biswas, A B Pardee

  • 1Dana-Farber Cancer Institute, Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts 02115, USA.

Journal of Cellular Biochemistry
|June 24, 2004
PubMed

Insights

This study proposes a novel chemotherapy that restores programmed cell death (apoptosis) in cancer cells by targeting the anti-apoptotic factor NF-kappaB, showing promise for treating tumors, especially in ER- breast cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Cancer cells often evade programmed cell death (apoptosis) through mutations, hindering effective treatment.
  • The transcription factor NF-kappaB plays a role in blocking apoptosis and is implicated in certain aggressive cancers.
  • Estrogen receptor-negative (ER-) breast cancers overexpressing EGFR present a specific challenge for current therapies.

Purpose of the Study:

  • To develop and demonstrate a chemotherapeutic strategy that re-establishes apoptosis in cancer cells.
  • To investigate the therapeutic potential of targeting NF-kappaB in ER- breast cancers.
  • To validate a tumor-specific chemotherapy approach.

Main Methods:

  • Developing a drug to re-establish nullified apoptosis in cancer cells.
  • Testing a specific chemotherapy against implanted tumors in mice.
  • Utilizing dominant-negative protein inhibitory peptides and small inhibitory RNAs (siRNAs) to investigate pathways.

Main Results:

  • Demonstrated the feasibility of a chemotherapy that restores apoptosis.
  • Showcased a therapy specific to cancer cells, leading to their death.
  • Identified NF-kappaB as a potential therapeutic target in specific breast cancer subtypes.

Conclusions:

  • Re-establishing apoptosis is a viable chemotherapeutic strategy.
  • Targeting NF-kappaB offers a promising approach for ER- breast cancer treatment.
  • Tumor-specific therapies that induce cancer cell death are advantageous over proliferation inhibitors.

More Related Videos

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...